PROTAC Market Expansion Driven by Growing Demand for Targeted Protein Degradation Therapies
Proteolysis Targeting Chimeras (PROTACs) represent a revolutionary therapeutic approach in drug development, combining protein degradation technology with targeted disease treatment. These bifunctional molecules are designed to selectively eliminate disease-causing proteins by facilitating their degradation through the cell's natural protein disposal system. PROTACs offer several advantages over traditional small molecule inhibitors, including higher specificity, lower drug resistance, and the ability to target previously "undruggable" proteins. The technology has gained significant attention in oncology, neurodegenerative disorders, and various other therapeutic areas due to its potential to address unmet medical needs. The growing interest in PROTAC technology stems from its ability to provide more effective and selective treatment options while minimizing side effects.
The Global PROTAC Market is estimated to be valued at USD 0.40 billion in 2024 and is expected to reach USD 2.59 billion by 2031, growing at a compound annual growth rate (CAGR) of 25.1% from 2024 to 2031.
The growing PROTAC Market Demand therapeutics is driven by their potential to address previously untreatable diseases and overcome limitations of conventional therapeutic approaches. Healthcare providers and patients are increasingly recognizing the benefits of targeted protein degradation, particularly in oncology and rare diseases. This has led to increased investment in PROTAC research and development, with numerous clinical trials currently underway.
Get More Insights On- PROTAC Market
Get this Report in Japanese Language: プロタック市場
Get this Report in Korean Language: PROTAC시장
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian